PharmaJet develops and markets needle-free devices for the vaccine delivery sector. The company markets its products under the Stratis brand name, a needle-free injection system that delivers medicine to intramuscular and subcutaneous tissue depths without needles.
- In June 2018, PharmaJet has entered into an exclusive global distribution agreement with Mundipharma.
- The agreement involves a 5-year stock order commitment by Mundipharma worth over $50 million.
Significance of the Transaction
The agreement grant PharmaJet’s access to over 120 countries and 6 continents through Mundipharma global distribution network. The partnership serves as an inflection point in the company’s Asian financing strategy.
- Healthios (Third500) served as strategic adviser to PharmaJet.
- This transaction highlights Healthios (Third500) commitment to capital formation for emerging growth companies, our success in completing complex transaction, and our dedication to deep, long-term relationships.
If you would like to learn more information about this transaction contact us below.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.